# Dose Confirmation Trial of AAV5-hFIXco-Padua

> **NCT03489291** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 3 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** AAV5-hFIXco-Padua (AMT-061)

## Key facts

- **NCT ID:** NCT03489291
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2018-10-30
- **Final completion:** 2023-09-21
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489291, "Dose Confirmation Trial of AAV5-hFIXco-Padua". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03489291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*